Literature DB >> 24788457

Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse.

Daniela Muhl1, Markus Kathmann, Carolin Hoyer, Laura Kranaster, Martin Hellmich, Christoph W Gerth, Johannes Faulhaber, Eberhard Schlicker, F Markus Leweke.   

Abstract

In previous studies, long-term cannabis use led to alterations of the endocannabinoid system including an increase in CB1 and/or CB2 receptor messenger RNA (mRNA) in blood cells and an increase in the serum level of the endocannabinoid 2-arachidonoyl glycerol. However, in those studies, cannabis use was stopped only few days before testing or not interrupted at all. Therefore, one cannot decide whether the alterations are due to long-term cannabis abuse or are confounded by acute effects of cannabis. Blood was sampled from donors that had smoked marijuana ≥20 times in their lives but had abstained from cannabis for ≥6 months (high-frequency users, HFU) and from controls (cannabis use ≤5 times lifetime). CB1 and CB2 mRNA was determined in peripheral mononuclear blood cells using the reverse transcriptase polymerase chain reaction. Serum anandamide level was assayed using electrospray tandem mass spectrometry. CB2 mRNA was increased by 45 % in HFU when compared to controls, whereas CB1 mRNA did not differ. The anandamide level in HFU exceeded that in controls by 90 %. Tobacco smoking could be excluded as a confounding factor. In conclusion, marijuana users that had smoked marijuana ≥20 times in their lives and stopped cannabis use at least 6 months before the study show an increase in CB2 receptor mRNA in the blood and in serum anandamide level. These alterations resemble those obtained for marijuana smokers that had stopped cannabis use only few days before testing and may be implicated in the pathogenesis of disorders associated with long-term cannabis use.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24788457     DOI: 10.1007/s00210-014-0984-2

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

Review 1.  Adverse health effects of non-medical cannabis use.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  Lancet       Date:  2009-10-17       Impact factor: 79.321

Review 2.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

3.  Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.

Authors:  J Romero; E Garcia-Palomero; J G Castro; L Garcia-Gil; J A Ramos; J J Fernandez-Ruiz
Journal:  Brain Res Mol Brain Res       Date:  1997-06

4.  Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry.

Authors:  Daniela Schreiber; Stephanie Harlfinger; Brit M Nolden; Christoph W Gerth; Ulrich Jaehde; Edgar Schömig; Joachim Klosterkötter; Andrea Giuffrida; Giuseppe Astarita; Daniele Piomelli; F Markus Leweke
Journal:  Anal Biochem       Date:  2006-12-20       Impact factor: 3.365

Review 5.  More surprises lying ahead. The endocannabinoids keep us guessing.

Authors:  Daniele Piomelli
Journal:  Neuropharmacology       Date:  2013-08-13       Impact factor: 5.250

6.  Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Authors:  F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

Review 7.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

8.  CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence.

Authors:  Andrea Rotter; Kristina Bayerlein; Max Hansbauer; Judith Weiland; Wolfgang Sperling; Johannes Kornhuber; Teresa Biermann
Journal:  Eur Addict Res       Date:  2012-08-28       Impact factor: 3.015

Review 9.  Chemical probes of endocannabinoid metabolism.

Authors:  Jacqueline L Blankman; Benjamin F Cravatt
Journal:  Pharmacol Rev       Date:  2013-03-19       Impact factor: 25.468

10.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors:  F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe
Journal:  Transl Psychiatry       Date:  2012-03-20       Impact factor: 6.222

View more
  6 in total

Review 1.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

2.  Changes in Expression of DNA-Methyltransferase and Cannabinoid Receptor mRNAs in Blood Lymphocytes After Acute Cannabis Smoking.

Authors:  Robert C Smith; Henry Sershen; David S Janowsky; Abel Lajtha; Matthew Grieco; Jon A Gangoiti; Ilya Gertsman; Wynnona S Johnson; Thomas D Marcotte; John M Davis
Journal:  Front Psychiatry       Date:  2022-07-04       Impact factor: 5.435

Review 3.  Exercise as an adjunctive treatment for cannabis use disorder.

Authors:  Angelique G Brellenthin; Kelli F Koltyn
Journal:  Am J Drug Alcohol Abuse       Date:  2016-06-17       Impact factor: 3.829

Review 4.  Keep off the grass? Cannabis, cognition and addiction.

Authors:  H Valerie Curran; Tom P Freeman; Claire Mokrysz; David A Lewis; Celia J A Morgan; Loren H Parsons
Journal:  Nat Rev Neurosci       Date:  2016-04-07       Impact factor: 38.755

5.  Cannabis Exposure Decreases Need for Blood Pressure Support During General Anesthesia in Orthopedic Trauma Surgery.

Authors:  Brent G Yeung; Michael W Ma; John A Scolaro; Ariana M Nelson
Journal:  Cannabis Cannabinoid Res       Date:  2021-07-05

6.  Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.

Authors:  Lara Milian; Manuel Mata; Javier Alcacer; María Oliver; María Sancho-Tello; José Javier Martín de Llano; Carlos Camps; José Galbis; Julian Carretero; Carmen Carda
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.